Key result
Evidence remains insufficient to support aspirin efficacy for CV prevention in elderly adults.
Why the study?
The role of aspirin in primary and secondary prevention in older adults is not well studied despite its frequent and long-term use.
Does aspirin improve outcomes in primary and secondary prevention in elderly adults?
Does aspirin improve outcomes in primary and secondary prevention in elderly adults?
This review examines the efficacy of aspirin for primary and secondary prevention in older adults and suggests relevant guidelines for practicing physicians.
Evidence gaps warrant caution prescribing aspirin for elderly prevention; leaves open net benefit pending dedicated trials.
Despite the frequency and long duration of aspirin use, its role in primary and secondary prevention in older adults is not well studied. This review takes a critical look at the available literature on aspirin efficacy in elderly adults, and some relevant guidelines for practicing physicians are suggested.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2012) studied this question. Aspirin efficacy for primary and secondary prevention in elderly adults remains insufficiently studied, necessitating a critical review of available literature to guide clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: